Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3335697 | Transfusion and Apheresis Science | 2012 | 4 Pages |
Abstract
Thrombotic thrombocytopenic purpura (TTP) is a rare disorder. Plasma exchange therapy has been shown to significantly reduce mortality in patients with TTP. Here, we report a case of TTP associated with ustekinumab therapy after a period of 2–3 years. Ustekinumab, a monoclonal antibody that inhibits interleukin 12 and interleukin 23, is one of the newer treatments for psoriasis. Although our patient experienced a prolonged course of TTP requiring 1 month of daily plasma exchange therapy, he recovered and remains in remission after 6 months.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Shih-Han S. Huang, A. Xenocostas, L.M. Moist, M. Crowther, J.C. Moore, W.F. Clark,